No Data
Jefferies Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $40
Oruka Therapeutics' Promising Long-Term Strategy and Advancements in Psoriasis Treatments Drive Buy Rating
Oruka Therapeutics to Present at Piper Sandler's 36th Annual Healthcare Conference
Oruka Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results.
LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $41
Strong Growth Potential for Oruka Therapeutics Driven by Robust Financials and Promising Drug Pipeline
No Data
No Data